Pfizer Investor Presentation — May 2021

Document content

Breakthroughs that change patients' lives ®

May 4, 2021First Quarter 2021

Earnings TeleconferenceIntroduction

Senior Vice President, Investor Relations 3

First Quarter 2021 EarningsForward-Looking Statements and Non-GAAP Financial Information

l Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could

cause actual results to differ materially from those expressed or implied by such statements. We include forward-looking statements about, among

other topics, our anticipated operating and financial performance, reorganizations, business plans and prospects, expectations for our product

pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial

results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits,

strategic reviews, capital allocation objectives, dividends and share repurchases, plans for and prospects of our acquisitions, dispositions and

other business development activities, and our ability to successfully capitalize on these opportunities, manufacturing and product supply, our

efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) and our investigational protease inhibitors, and our

expectations regarding the impact of COVID-19 on our business, operations and financial results. These statements are subject to risks,

uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results.

Additional information regarding these and other factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended